Why Are Some People Against Ibogaine?

Iboga has enthusiasts who talk about it like it saved their life. Some of them are right. It also has critics who raise concerns that deserve honest engagement, not dismissal. If you're considering iboga, you should hear both sides from someone who works with the medicine and takes the criticisms seriously.

The safety argument.

This is the most legitimate criticism and the one I agree with most.

Ibogaine has a fatality rate. Estimated at 1 in 300 to 1 in 1,000 across all reported administrations. That's higher than almost any other psychoactive substance used therapeutically. For comparison, the fatality rate for psilocybin and LSD in clinical settings is effectively zero.

Critics point out that ibogaine is being administered in largely unregulated settings, often without proper medical screening, cardiac monitoring, or emergency preparedness. They're right. The majority of iboga-related deaths were preventable — they happened because someone cut corners on safety.

The counterargument isn't that iboga is safe — it's that iboga is manageable when safety protocols are followed rigorously. But "manageable when done right" is a weaker guarantee than "inherently safe," and the current landscape has too many providers doing it wrong. This is a fair criticism.

The cultural appropriation argument.

Iboga comes from the Bwiti tradition of Central West Africa. It's been held by the Babongo, Mitsogo, and Fang peoples of Gabon for generations. It's a sacrament, not a supplement.

Critics argue that Western providers — particularly those without any connection to the tradition — are extracting the medicine from its cultural context, commodifying it, and profiting while the communities that hold the tradition see little or no benefit. This criticism has teeth.

Some providers use the language of Bwiti without any real relationship to it. They borrow the aesthetics — the music, the imagery, the ceremonial language — without understanding or respecting the source. They treat iboga as a pharmacological tool that happens to come with a colorful cultural wrapper. That's extraction.

The honest response isn't to dismiss this criticism — it's to take it seriously and act differently. That means maintaining a real relationship with the tradition and its holders. Supporting the communities financially and practically. Being transparent about lineage and training. Acknowledging that you are a guest in someone else's tradition, not its owner. This is why my Gabon work runs through Ebando and Tatayo — not because it looks good on a website, but because the relationship with the source is the integrity check for everything else.

The evidence gap.

Medical researchers and addiction specialists point out that the evidence base for ibogaine, while promising, is thin. There are no large-scale randomized controlled trials. The clinical data comes from retrospective studies, observational studies, and case reports. The sample sizes are small. The long-term outcome data is limited.

This is factually correct. The evidence is strongest for short-term opioid withdrawal interruption and weakest for long-term outcomes, optimal dosing, and comparative efficacy against other treatments. Anyone who tells you ibogaine is a "proven cure" is overstating what the science supports.

The counterargument is that ibogaine's legal status in most countries makes controlled research extremely difficult, and the observational evidence that does exist is remarkably consistent. But "consistent observational evidence" is not the same as "proven," and intellectual honesty requires holding that distinction.

The unregulated provider problem.

There is no governing body for iboga facilitation. No licensure. No standardized training. No minimum safety requirements. Anyone can call themselves a facilitator, rent a space, source medicine, and start working with people.

This means the range of quality in the iboga space is enormous. On one end, you have providers with deep traditional training, rigorous medical screening, continuous cardiac monitoring, and years of experience. On the other end, you have people with a weekend workshop and a Telegram connection for sourcing root bark.

Critics argue that without regulation, there's no way for a consumer to reliably distinguish between these extremes. They're mostly right. The burden of vetting falls entirely on the person seeking treatment, and most people don't know what questions to ask. Until regulation catches up — and in some jurisdictions like Oregon, it's beginning to — the responsibility falls on providers to hold themselves to a standard higher than the minimum.

The "it's not for everyone" problem.

Enthusiasts sometimes present iboga as a universal solution. Depression? Iboga. Anxiety? Iboga. Relationship problems? Iboga. Career dissatisfaction? Iboga. This overclaiming damages credibility and sets people up for disappointment.

Iboga is powerful. It's not for everyone. It's not for every condition. It's contraindicated for a significant portion of the population on medical grounds alone. And for many people, other approaches — therapy, MAT, psilocybin, lifestyle changes — are safer, more accessible, and equally effective for what they're dealing with. The honest position is that iboga occupies a specific niche.

The psychedelic tourism concern.

Some critics worry that iboga is becoming the next stop on the psychedelic tourism circuit — after ayahuasca, after psilocybin, before whatever comes next. People chasing experiences rather than doing genuine work.

This is a real concern. Someone who treats iboga as a bucket-list item is unlikely to do the preparation, take the screening seriously, or commit to integration. They're consuming an experience, not engaging with a medicine. The filter for this is honest screening. Not everyone who wants iboga should get it. A responsible provider says no more often than the market rewards, and that's by design.

Where I land.

I take every one of these criticisms seriously. The safety risks are real and I screen aggressively. The cultural appropriation concern is valid and I maintain active relationship with the tradition through Ebando. The evidence gap is real and I don't overclaim. The unregulated market is a problem and I hold myself to standards that I'd want if I were the one sitting.

The criticisms don't make iboga wrong. They make the way iboga is often handled wrong. The medicine is extraordinary. The industry around it is uneven. Both things are true.

Related reading: Real risks and safety measures and the Bwiti tradition.